Biotest BIO.DE XETRA down 0.94% after hours 11 Feb 2026: oversold bounce

BIO.DE stock slipped to EUR 42.20 (-0.94%) in after hours trading on 11 Feb 2026, putting the shares in a short-term oversold zone. Trade volume was light at 175.00 shares versus an average of 129.00, but relative volume of 1.36 shows above-normal interest for late trading on XETRA in Germany. The pullback follows a failure to hold intraday gains near the year high of EUR 43.20, creating a tactical oversold bounce opportunity for traders who respect risk limits and use tight stops.

Price action and technical setup for BIO.DE stock

BIO.DE stock closed at EUR 42.20 after hours with a day range EUR 42.20–43.00 and a year range EUR 40.40–43.20. The 50-day average sits at EUR 42.54 and the 200-day average at EUR 41.71, so price is near key short-term support.

The oversold bounce idea is supported by low intraday volatility and a rising relative volume (1.36). For traders, a cliff below EUR 40.40 (year low) invalidates the bounce thesis and suggests cutting exposure.

Fundamentals and valuation for BIO.DE stock

Biotest (BIO.DE) reports EPS -0.63 and a trailing PE of -66.98, reflecting recent losses. Key ratios: P/S 2.92, P/B 3.22, Debt/Equity 1.31, and Current Ratio 4.93, showing liquidity but operating pressure on margins.

Enterprise value is EUR 2,023,770,640.00 and market cap is EUR 1,396,870,640.00. These figures indicate the stock trades on valuation multiples that demand a recovery in margins and cash flow to re-rate higher.

Meyka AI rates and model forecast for BIO.DE stock

Meyka AI rates BIO.DE with a score out of 100: 70.90 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 and sector comparison, financial growth, key metrics, forecasts, analyst signals, and industry performance.

Meyka AI’s forecast model projects a 1‑year price near EUR 42.05, compared with the current EUR 42.20, implying roughly -0.35% from today. Forecasts are model-based projections and not guarantees, and they assume no material operational surprises.

Catalysts, risks and sector context for BIO.DE stock

Near-term catalysts include improved plasma collection trends and product uptake in hematology and immunology; the next material event on file is an earnings announcement on 2025-11-10. The healthcare sector in Germany is trading mixed, with sector 1D performance at +1.45%, which can help sentiment for Biotest.

Key risks are slow margin recovery, high inventory days (500.13) and weak cash flow metrics (free cash flow per share -1.87). Elevated debt-to-equity raises sensitivity to revenue shocks.

Trading strategy: oversold bounce play for BIO.DE stock

For an oversold bounce, consider a staged entry between EUR 41.70 (200-day average) and EUR 42.20 with a tight stop below EUR 40.40 to limit downside. Short-term profit target one: EUR 43.20 (recent year high). Target two for momentum traders: EUR 46.00 if volume and sector strength confirm the move.

Use position sizing that limits downside to no more than 1–2% of portfolio value per trade. This is a tactical trading setup, not a long-term recommendation.

Liquidity, volume and execution notes for BIO.DE stock

Trading liquidity is thin: today’s volume 175.00 vs average 129.00, so expect wider spreads on XETRA in after hours. Execution risk is material when volume is below 1,000 shares.

If you plan to trade the oversold bounce, use limit orders, avoid market orders after hours, and monitor intraday volume spikes above 1,000.00 shares to confirm renewed buying interest.

Final Thoughts

Key takeaway: BIO.DE stock is at EUR 42.20 after hours on 11 Feb 2026, showing a modest pullback that fits an oversold bounce setup but requires strict risk control. Meyka AI’s model gives a 12‑month projection near EUR 42.05 (implied -0.35% vs current price), so the near-term trade is tactical rather than a strong directional call. Use a stop below EUR 40.40 (year low) and initial targets at EUR 43.20 and EUR 46.00 if momentum and volume confirm. Remember this analysis uses Meyka AI’s data and models; forecasts are projections, not guarantees. Check liquidity on XETRA and confirm catalysts before adding exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.